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In 1989, a Note describing the nomenclature for tetracycline resistance determinants which employed letters of the English alphabet was published in this journal (14) . Since no letters now remain for designating additional determinants, we propose that new determinants be hereafter designated by Arabic numerals. The new system is patterned on the previous letterbased one, with a numeral used instead of a letter to name a determinant. Since 30 determinants have been described (most, but not all, according to the 1989 nomenclature, with the new 1999 nomenclature being used for Tet 30) (Table 1) , the next determinant would receive number 31, with no renaming of the earlier determinants. Following the previous system used with letters, the class would be 31, and the determinant would be designated Tet 31 (with a space between "Tet" and "31"). If there were only a single gene in the determinant, it would be designated tet (31) . If there were more than one structural gene, the first would be designated tetA (31) and the second would be tetB (31) , etc. A regulatory gene would be designated tetR (31) . Note that the class designation, 31, is not italicized. The names of the corresponding proteins would be Tet (31) or TetA(31), etc. An allele of a gene would be designated by a hyphen followed by an italicized allele number; for example, tetA(31)-1 would be allele number 1 of the tetA gene of class 31. If the class designation is not needed within a single communication, it could be omitted.
This system employs some of the conventions from the previous communication (14) and is summarized in Table 2 . Usage for previously described determinants should continue to conform to the prior recommendations (14) .
Recently, there have been several situations in which tetracycline resistance determinants discovered in different laboratories were nearly given the same designation. To avoid such a problem in the future, we offer the S. B. Levy group to coordinate the naming of new determinants. Such a determinant can be defined as a naturally occurring unit of one or more adjacent genes involved primarily in tetracycline resistance (as opposed to multidrug resistance or other known function) having a sequence significantly different from sequences of currently known determinants. We suggest Յ80% amino acid identity as the dividing line, based on previous usage. Class L has been defined as a single class even though it contains two subgroups a In most cases, we cite the first publication to report the sequence for one or both genes of a determinant. In cases where major (but not minor) errors were later corrected, we cite the later publication. The sequences of many variants of some determinants (particularly Tet L and Tet M) are available but are not given here. Four different unnamed and unsequenced but presumed ribosomal protection determinants (5) in which the single proteins only are 81% identical (25, 26) , while the proteins of two different classes, M and S, are 79% identical (4, 25) . To confirm that a number proposed for a newly discovered tetracycline resistance determinant has not been used, please contact S. B. Levy. Finally, we note that when looking in databases for a name containing parentheses or a space, such as "tet(X)" or "Tet X", quotation marks should be used around the name, as shown, to retrieve the term intact.
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